Title:Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases
Volume: 28
Issue: 8
Author(s): Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz, Negar Ghanaatian, Parichehr Kohansal, Mohammad Hosein Farzaei, Khashayar Afshari, Amirhossein Sahebkar*Amir Hossein Abdolghaffari*
Affiliation:
- Halal Research Center of IRI, FDA, Tehran,Iran
- Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran,Iran
Keywords:
Gastroenterology, inflammatory bowel disease, ulcerative colitis, crohn’s disease, mammalian target of
rapamycin, natural products.
Abstract: Inflammatory bowel disease (IBD) is a general term for a group of chronic and progressive
disorders. Several cellular and biomolecular pathways are implicated in the pathogenesis of
IBD, yet the etiology is unclear. Activation of the mammalian target of rapamycin (mTOR) pathway
in the intestinal epithelial cells was also shown to induce inflammation. This review focuses
on the inhibition of the mTOR signaling pathway and its potential application in treating IBD. We
also provide an overview of plant-derived compounds that are beneficial for the IBD management
through modulation of the mTOR pathway. Data were extracted from clinical, in vitro and in vivo
studies published in English between 1995 and May 2019, which were collected from PubMed,
Google Scholar, Scopus and Cochrane library databases. Results of various studies implied that
inhibition of the mTOR signaling pathway downregulates the inflammatory processes and cytokines
involved in IBD. In this context, a number of natural products might reverse the pathological
features of the disease. Furthermore, mTOR provides a novel drug target for IBD. Comprehensive
clinical studies are required to confirm the efficacy of mTOR inhibitors in treating IBD.
